This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2025 Aug 7;146(6):652-653.

doi: 10.1182/blood.2025029342.

Sustained MRD negativity: robust, not all-powerful

Aurore Perrot¹, Jill Corre²

Affiliations

PMID: 40773177
DOI: 10.1182/blood.2025029342

Editorial

Sustained MRD negativity: robust, not all-powerful

Aurore Perrot et al. Blood. 2025.

. 2025 Aug 7;146(6):652-653.

doi: 10.1182/blood.2025029342.

Authors

Aurore Perrot¹, Jill Corre²

Affiliations

¹ Toulouse University.
² Institut Universitaire du Cancer de Toulouse-Oncopole.

PMID: 40773177
DOI: 10.1182/blood.2025029342

No abstract available

PubMed Disclaimer

Comment on

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.
Giri S, Dhakal B, Callander NS, Medvedova E, Godby K, Dholaria BR, Bal S, Ravi G, Chhabra S, Silbermann RW, Costa L. Giri S, et al. Blood. 2025 Aug 7;146(6):707-716. doi: 10.1182/blood.2024027674. Blood. 2025. PMID: 40193714 Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems